The clinical diagnosis and treatment decision for CPP are mainly based on auxiliary tests such as gonadotropin level (LH, FSH), gonad size, and bone age, with the peak LH value and the ratio of the LH peak value to the FSH peak value after the GnRH excitation test serving as the gold standard for early diagnosis. The gene discussed is BRD2; the disease is central precocious puberty.